LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Apellis Pharmaceuticals Inc

Fermé

SecteurSoins de santé

18.79 -2.34

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.65

Max

18.87

Chiffres clés

By Trading Economics

Revenu

-56M

-92M

Ventes

-46M

167M

BPA

-0.74

Marge bénéficiaire

-55.292

Employés

705

EBITDA

-56M

-80M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+95.59% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-119M

2.4B

Ouverture précédente

21.13

Clôture précédente

18.79

Sentiment de l'Actualité

By Acuity

54%

46%

315 / 381 Classement par Healthcare

Apellis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 juin 2025, 22:33 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380 Million

14 juin 2025, 01:24 UTC

Acquisitions, Fusions, Rachats

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 juin 2025, 23:50 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 juin 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 juin 2025, 23:09 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 juin 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 juin 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380M

13 juin 2025, 22:04 UTC

Market Talk
Acquisitions, Fusions, Rachats

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 juin 2025, 21:42 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 juin 2025, 21:35 UTC

Acquisitions, Fusions, Rachats

Bunge: Outside Date Extended to July 3

13 juin 2025, 21:35 UTC

Acquisitions, Fusions, Rachats

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 juin 2025, 21:34 UTC

Acquisitions, Fusions, Rachats

Bunge Gets Mexico Approval for Viterra Deal

13 juin 2025, 21:32 UTC

Acquisitions, Fusions, Rachats

Bunge Gets China Approval for Viterra Deal

13 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 juin 2025, 20:45 UTC

Acquisitions, Fusions, Rachats

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 juin 2025, 20:34 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 juin 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 juin 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 juin 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 juin 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 juin 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 juin 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 juin 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Comparaison

Variation de prix

Apellis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

95.59% hausse

Prévisions sur 12 Mois

Moyen 36.83 USD  95.59%

Haut 60 USD

Bas 18 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

20 ratings

12

Achat

8

Maintien

0

Vente

Sentiment

By Acuity

315 / 381Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.